{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:02:48Z","timestamp":1792807368733,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023280","name":"CSL Seqirus Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126791","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:21:14Z","timestamp":1739362874000},"page":"126791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50\u00a0years and older"],"prefix":"10.1016","volume":"51","author":[{"given":"Brandon J.","family":"Essink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"de Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Isakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank R.","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126791_bb0010","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126791_bb0015","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cid\/cis211","article-title":"Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008","volume":"54","author":"Zhou","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"Krammer","year":"2018","journal-title":"Influenza Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2025.126791_bb0035","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","article-title":"Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes","volume":"29","author":"Calabro","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126791_bb0040","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126791_bb0045","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.126791_bb0050","series-title":"FLUAD\u00ae PI","author":"Food & Drug Administration","year":"2025"},{"key":"10.1016\/j.vaccine.2025.126791_bb0060","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the safety and immunogenicity of an MF59\u00ae-Adjuvanted with a non-Adjuvanted seasonal influenza vaccine in elderly subjects","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126791_bb0075","first-page":"11","article-title":"Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness","author":"Rockman","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126791_bb0080","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126791_bb0085","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1086\/381165","article-title":"Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons","volume":"189","author":"Hak","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0100","volume":"13","author":"Bernard","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126791_bb0110","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase","volume":"207","author":"Couch","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0115","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/cid\/ciz639","article-title":"Pre-existing Antineuraminidase antibodies are associated with shortened duration of influenza a(H1N1)pdm virus shedding and illness in naturally infected adults","volume":"70","author":"Maier","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.vaccine.2019.11.041","article-title":"Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: introducing a neuraminidase titration reagent","volume":"38","author":"Gao","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126791_bb0130","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1172\/JCI57834","article-title":"Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies","volume":"121","author":"Sasaki","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.126791_bb0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.vaccine.2019.10.058","article-title":"A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults\u00a0\u2265\u00a065 years of age","volume":"38","author":"Otten","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126791_bb0140","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1473-3099(20)30694-0","article-title":"Prevention of influenza during mismatched seasons in older adults with an MF59-Adjuvanted Quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study","volume":"21","author":"Beran","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0145","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/vaccines11101528","article-title":"Immunogenicity and safety of MF59-Adjuvanted Quadrivalent influenza vaccine compared with a Nonadjuvanted, Quadrivalent influenza vaccine in adults 50&ndash;64 years of age","volume":"11","author":"Poder","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.126791_bb0150","first-page":"ofad429","article-title":"Additional burden averted in the US from use of MF59-Adjuvanted seasonal influenza vaccine compared with standard seasonal influenza vaccine among adults \u226565 years. Open forum","volume":"10","author":"McGovern","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2025.126791_bb0155","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/infdis\/jiy716","article-title":"Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018","volume":"220","author":"Izurieta","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0160","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/infdis\/jiaa080","article-title":"Relative effectiveness of influenza vaccines among the United States elderly, 2018-2019","volume":"222","author":"Izurieta","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.933440","article-title":"Antigenic alteration of 2017-2018 season influenza B vaccine by egg-culture adaption","volume":"2","author":"Wilson","year":"2022","journal-title":"Front Virol"},{"key":"10.1016\/j.vaccine.2025.126791_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146138","article-title":"Age-specific effects of vaccine egg adaptation and immune priming on a(H3N2) antibody responses following influenza vaccination","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.126791_bb0175","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/nm.4223","article-title":"Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain","volume":"22","author":"Raymond","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.126791_bb0180","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.3390\/ijerph17155423","article-title":"Retrospective assessment of the antigenic similarity of egg-propagated and cell culture-propagated reference influenza viruses as compared with circulating viruses across influenza seasons 2002-2003 to 2017-2018","volume":"17","author":"Rajaram","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2025.126791_bb0185","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126791_bb0190","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126791_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101331","article-title":"Comparative efficacy and safety of vaccines to prevent seasonal influenza: a systematic review and network meta-analysis","volume":"46","author":"Minozzi","year":"2022","journal-title":"EClinicalMedicine"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2025.127127","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:40:32Z","timestamp":1762278032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"alternative-id":["S0264410X2500088X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126791","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50\u00a0years and older","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126791"}}